Placebo for Odanacatib

DRUG2 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

OsteoporosisPostmenopausal Osteoporosis

Phase 3

A Study of MK-0822 in Postmenopausal Women With Osteoporosis to Assess Fracture Risk (MK-0822-018)

TerminatedNCT00529373

Merck Sharp & Dohme LLCPostmenopausal Osteoporosis

Start: 2007-09-13End: 2017-02-01Updated: 2024-06-11

A Study to Assess Safety and Efficacy of Odanacatib (MK-0822) in Men With Osteoporosis (MK-0822-053)

CompletedNCT01120600

Merck Sharp & Dohme LLCOsteoporosis

Start: 2010-06-09End: 2013-07-22Updated: 2018-08-28

Related Papers

Effects of odanacatib on bone-turnover markers in osteoporotic postmenopausal women: a post hoc analysis of the LOFT study.

2022-06-171 citations

Incidence of Hip and Subtrochanteric/Femoral Shaft Fractures in Postmenopausal Women With Osteoporosis in the Phase 3 Long-Term Odanacatib Fracture Trial

Journal of Bone and Mineral Research2020-12-0126 citations

Randomized, controlled trial to assess the safety and efficacy of odanacatib in the treatment of men with osteoporosis.

2020-11-178 citations

Effects of Odanacatib on Bone Structure and Quality in Postmenopausal Women With Osteoporosis: 5-Year Data From the Phase 3 Long-Term Odanacatib Fracture Trial (LOFT) and its Extension

Journal of Bone and Mineral Research2020-03-0229 citations

Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.

2019-10-31119 citations